Lupin Launches Generic Antibiotics and Antiviral Tablets in the US Market

Lupin has introduced generic versions of Doxycycline for Injection and Letermovir Tablets in the US after receiving approval from the USFDA. Doxycycline targets bacterial infections, while Letermovir prevents cytomegalovirus. These products compete with Pfizer's Vibramycin and Merck's Prevymis, respectively, and had combined annual US sales of $362 million.

In a strategic move to expand its footprint in the US market, Mumbai-based pharmaceutical giant Lupin announced on Monday the launch of two generic medications. The company has introduced Doxycycline for Injection USP, following approval from the US Food and Drug Administration (USFDA).

This product, which is a generic equivalent of Pfizer Inc's Vibramycin for Injection, aims to treat or prevent bacterial infections and curb the rise of drug-resistant bacteria. According to IQVIA MAT April 2024 data, Doxycycline for Injection USP had an estimated annual sale of USD 48 million in the US.

Furthermore, Lupin has received tentative approval from the USFDA for its abbreviated new drug application for Letermovir Tablets (240 mg and 480 mg). A generic counterpart of Merck Sharp & Dohme LLC's Prevymis tablets, Letermovir is designed to prevent cytomegalovirus (CMV) infections. This product fetched an estimated annual sale of USD 314 million in the US, per IQVIA MAT April 2024 data.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)